AstraZeneca has not began phase 2 of the seamless phase 1/2 clinical trial of AZD0466 yet
JF & Co. state in the December 2021 Shareholder Newsletter dated 16 Dec 2021 and again in the recent Quarterly report issued on 28 January 2022 the complete opposite ?
Content from Shareholder Newsletter Dec 2021
Who to believe I wonder given the phase 1 trial has finished and JF & Co. state as recent as December and again in January that they are "actively enrolling patients" ? lol
Content from Quarterly Jan 2022
I also wonder if the 100 years of commercial experience was smart enough to secure additional upfront milestone payments in the AstraZeneca agreement when a new trial is started using the same drug ... for example; AZD0466
Are Starpharma entitled to another milestone payment for this new trial starting this month (Feb) if it is the same DEP drug already being trialed for a different treatment or will AstraZeneca be able to say yeah, nah ... no money for you as it is the same indication ??
SPL Price at posting:
$1.03 Sentiment: Hold Disclosure: Held
